抗栓治疗对ST段抬高心肌梗死患者的疗效及超敏C反应蛋白的影响

The influence of antithrombotic therapy on the curative effect and high sensitivity C reactive protein for patients with ST segment elevation myocardial infarction

目的探讨抗栓治疗对ST段抬高心肌梗死(STEMI)患者的疗效及超敏C反应蛋白(hsCRP)的影响。方法将本院2008年6月～2009年12月收治的60例STEMI患者分为治疗组和对照组,对照组采用常规抗栓治疗,治疗组在对照组的基础上加用替罗非班治疗,比较两组患者的临床疗效及hsCRP的变化。结果治疗组的总有效率为83.3%,显著高于对照组的66.7%(P<0.05);且治疗组的hsCRP的改善显著优于对照组(P<0.05)。结论替罗非班是治疗STEMI较为有效的抗栓药物,其能显著降低患者的炎性反应,缓解症状。

Objective To investigate the influence of antithrombotic therapy＂ on the curative effect and high sensitivity C reactive protein for patients with ST segment elevation myocardial infaretion（STEMI）. Methods Sixty cases of STEMI in our hospital from June 2008 to December 2009 were divided into the treatment group and the control group, the control group was given conventional antithrombotie therapy, the treatment group was given tirofiban on the basis of the control group, the two groups were compared by the clinical curative effect and the changes of hsCRP. Results The effective rate in the treatment group （83.3%） was significantly higher than that of control group （66.7%） （P 〈 0.05）; and the improvement of hsCRP in the treatment group was better than the control group （P 〈 0.05）. Conclusion Tirofiban is one of the effective antithrombotic drugs for STEMI which can significantly decreased the inflammatory response of the patients, and relieves the symptoms.